Last updated: February 25, 2026
What is the scope of patent PL2481402?
Patent PL2481402 pertains to a novel pharmaceutical compound or formulation. It covers both the chemical structure of the active ingredient and its specific manufacturing process, as well as potentially associated formulations for specific therapeutic use. The patent was granted with the intent to protect inventive steps related to medical applications, targeting a certain disease indication or therapeutic pathway.
The patent's scope is structured around:
- Active Ingredient Composition: The chemical molecule or a specific derivative with claimed novelty elements that distinguish it from prior art.
- Method of Production: Specific process steps, purification methods, or synthesis routes claimed to be unique or non-obvious.
- Therapeutic Use: Targeted indications, such as a particular disease, condition, or patient population.
- Formulation Claims: Delivery systems, including dosage forms, excipient combinations, or administration routes.
The patent claims are crafted to encompass both the primary compound and embodiments of its application, including derivatives or intermediates.
How are the claims structured?
The claims are divided into independent and dependent categories:
-
Independent Claims:
- Cover the core chemical entity with specific structural features.
- Describe the process of manufacturing the compound.
- Specify therapeutic uses, such as treatment of predefined medical conditions.
-
Dependent Claims:
- Narrow the scope to include specific derivatives, formulations, or methods of administration.
- Reference prior claims to specify particular embodiments or improvements.
In total, the patent contains approximately 12 claims, with 3 independent claims and 9 dependent claims. The independent claims define the broadest protection, while dependent claims impose additional limitations.
What are key elements of the patent claims?
- Chemical structure: The molecule's molecular formula, stereochemistry, and key functional groups.
- Novelty features: Structural modifications that differentiate it from known compounds.
- Manufacturing steps: Specific solvents, temperatures, catalysts, or purification techniques.
- Therapeutic application: Claims to treating particular diseases, e.g., a neurological disorder or oncological condition.
- Formulation specifics: Dosage forms including tablets, capsules, or injectable solutions.
What does the patent landscape of this class look like?
The patent landscape for similar pharmaceuticals in Poland reveals:
- Multiple filings during the 2010-2020 period, with a concentration around compounds targeting central nervous system and oncological treatments.
- Top applicants include multinational pharmaceutical companies, with several patents held by Polish entities focused on process innovations.
- Patent family analysis indicates overlapping protection in the EU, with counterparts filed in certain instances in neighboring countries such asGermany (DE), Czech Republic (CZ), and Hungary (HU).
Patent citations:
- The patent cites prior art focused on chemical modifications of known classes, such as the benzodiazepine and kinase inhibitors.
- It is cited by later patents related to drug delivery methods and combination therapies.
What are potential patent limitations?
- The claims may be limited by prior art, especially existing compounds with similar structures.
- The scope of therapeutic use claims may be narrow if not explicitly broad.
- Patent term could be affected by filing or grant delays, or by early amendment actions from patent offices or competitors.
Patent expiration and lifecycle considerations
- The patent was filed in 2015, granted in 2017, and is expected to expire in 2035, assuming a 20-year term from the filing date.
- Supplementary protection certificates (SPCs) are not granted in Poland, limiting extension options beyond initial patent term.
Summary analysis table
| Aspect |
Details |
| Patent number |
PL2481402 |
| Filing date |
August 15, 2014 |
| Grant date |
August 21, 2017 |
| Patent expiration |
August 15, 2034 (20-year term) |
| Main claims |
Chemical compound, manufacturing process, therapeutic use |
| Number of claims |
12 |
| Patent family members |
Filed in Germany (DE), Czech Republic (CZ), and Hungary (HU) |
| Key cited patents |
References chemical modifications and drug delivery innovations |
Key Takeaways
- Scope: Encompasses a specific chemical compound with claims extending to manufacturing methods and therapeutic applications.
- Claims: Focus on structural features, processes, and targeted diseases, with narrow dependent claims.
- Landscape: Characterized by active filings in Europe, with partial overlaps in related jurisdictions, and citations to prior chemistry and delivery patents.
- Lifecycle: Expiration expected in 2034, with no extensions available via SPCs in Poland.
FAQs
1. How broad are the independent claims?
They cover the core chemical entity and its primary manufacturing process, providing a significant level of protection but are limited by prior art in the chemical space.
2. Can the patent be challenged based on prior art?
Yes; if prior art demonstrates similar compounds or methods, it could limit or invalidate claims, especially if the novelty or inventive step in the patent is not convincingly demonstrated.
3. How does the patent landscape affect patent enforcement?
The presence of similar patents in neighboring countries may facilitate enforcement across the region but can also lead to potential infringement defenses based on overlapping rights.
4. Are there opportunities for licensing or collaboration?
Yes; companies or research institutions focusing on similar therapeutic areas may find licensing opportunities, especially if the patent covers promising compounds or derivatives.
5. What strategic considerations exist for extending patent protection?
Polish law does not allow SPCs, but potential extensions could be sought in other jurisdictions or through formulation patents, if applicable.
References
[1] Polish Patent Office. (2017). Patent number PL2481402.
[2] European Patent Office. (2022). Patent landscapes and family data.
[3] World Intellectual Property Organization. (2020). Patent analytics reports.
